Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
IKT Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 09, 2026
Report Source: 2026 1st Quarter Report
Inhibikase Therapeutics Inc. Stock Analysis IKT
United States Health Care Micro Cap Report: Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Read More Inhibikase Therapeutics Inc (IKT) Chart
Key Statistics of Inhibikase Therapeutics Inc (IKT)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.82Volume
546.30KP/E Ratio (TTM)
-52 Week Range
Market Cap
229.74MAvg. Volume
586.55KDividend Yield
-Financial Metrics & Statements of Inhibikase Therapeutics Inc (IKT)
FAQ's for Inhibikase Therapeutics Inc (IKT)
- According to Musaffa’s Shariah screening methodology, Inhibikase Therapeutics Inc (IKT) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Inhibikase Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Inhibikase Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Inhibikase Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Inhibikase Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Inhibikase Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.